A single base pair mutation encoding a premature stop codon in the MIS type II receptor is responsible for canine persistent Müllerian duct syndrome

Journal of Andrology

Volumn 30, Issue 1, 2009, Pages 46-56

  Wu, Xiufeng ^a   Wan, Shengqin ^a   Pujar, Shashikant ^b   Haskins, Mark E ^b   Schlafer, Donald H ^c   Lee, Mary M ^a   Meyers Wallen, Vicki N ^a,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AMH type II receptor (AMHR2); Anti M llerian hormone; Dog; M llerian duct regression

Indexed keywords

HORMONE RECEPTOR; MUELLERIAN INHIBITING FACTOR 2 RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; BASE PAIRING; CONTROLLED STUDY; DOG; FEMALE; GENE MUTATION; GENOTYPE; HOMOZYGOSITY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PEDIGREE ANALYSIS; PERSISTENT MUELLERIAN DUCT SYNDROME; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOP CODON; TRANSLATION REGULATION; UROGENITAL TRACT DISEASE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CODON, NONSENSE; DNA MUTATIONAL ANALYSIS; DOGS; GENES, RECESSIVE; GENITALIA; GONADAL DYSGENESIS; MALE; MOLECULAR SEQUENCE DATA; PEDIGREE; PHENOTYPE; POINT MUTATION; RECEPTORS, PEPTIDE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 58149305710     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.108.005736     Document Type: Article

References (55)

1. Allard S, Adin P, Gouedard L, di Clemente N, Josso N, Orgebin-Crist MC, Picard JY, Xavier F. Molecular mechanisms of hormone-mediated Müllerian duct regression: involvement of beta-catenin. Development. 2000;127:3349-3360.
2. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403-410.
3. Amann RP. Use of animal models for detecting specific alterations in reproduction. Fund Appl Toxicol. 1986;2:13-26.
4. Baarends WM, van Helmond MJ, Post M, van der Schoot PJ, Hoogerbrugge JW, de Winter JP, Uilenbroek JT, Karels B, Wilming LG, Meijers JH, Themmen APN, Grootegoed JA. A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Müllerian duct. Development. 1994;120:189-197.
5. Belville C, Josso N, Picard JY. Persistence of Müllerian derivatives in males. Am J Med Genet. 1999;89:218-223.
6. Belville C, Van Vlijmen H, Ehrenfels C, Pepinsky B, Rezaie AR, Picard JY, Josso N, di Clemente N, Cate RL. Mutations of the anti-Müllerian hormone gene in patients with persistent Müllerian duct syndrome: biosynthesis, secretion, and processing of the abnormal proteins and analysis using a three-dimensional model. Mol Endocrinol. 2004;18:708-721.
7. Brook CG, Wagner H, Zachmann M, Prader A, Armendares S, Frenk S, Aleman P, Najjar SS, Slim MS, Genton N, Bozic C. Familial occurrence of persistent Müllerian structures in otherwise normal males. Br Med J. 1973;1:771-773.
8. Brown TT, Burek JD, McEntee K. Male pseudohermaphroditism, cryptorchidism and Sertoli cell neoplasia in three miniature schnauzers. J Am Vet Med Assoc. 1976;169:821-825.
9. di Clemente N, Belville C. Anti-Müllerian hormone receptor defect. Best Pract Res Clin Endocrinol Metab. 2006;20:599-610.
10. di Clemente N, Wilson C, Faure E, Boussin L, Carmillo P, Tizard R, Picard JY, Vigier B, Josso N, Cate R. Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone. Mol Endocrinol. 1994;8:1006-1020.
11. Donahoe PK, Ito Y, Marfatia S, Hendren WH. The production of Müllerian inhibiting substance by the fetal, neonatal and adult rat. Biol Reprod. 1976; 15:329-334.
12. Donahoe PK, Ito Y, Marfatia S, Hendren WH. A graded organ culture assay for the detection of Müllerian inhibiting substance. J Surg Res. 1977a;23:141-148.
13. Donahoe PK, Ito Y, Morikawa Y, Hendren WH. Müllerian inhibiting substance in human testes after birth. J Surg Res. 1977b;12:323-330.
14. Donahoe PK, Ito Y, Price M, Hendren WH. Müllerian inhibiting substance in bovine fetal, newborn and prepubertal testes. Biol Reprod. 1977c;16:238-243.
15. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology. 1999;140:5789-5796.
16. Fallat ME, Siow Y, Belker AM, Boyd JK, Yoffe S, MacLaughlin DT. The presence of Müllerian inhibiting substance in human seminal plasma. Hum Reprod. 1996;11:2165-2169.
17. Fallat ME, Siow Y, Klar EA, Belker AM, MacLaughlin DT. The presence of Müllerian inhibiting substance binding sites in human sperm. J Urol. 1998;159:2210-2214.
18. Gouedard L, Chen YG, Thevenet L, Racine C, Borie S, Lamarre I, Josso N, Massague J, di Clemente N. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. J Biol Chem. 2000;275:27973-27978.
19. Guerrier D, Tran D, Vanderwinden JM, Hideux S, Van Outryve L, Legeai L, Bouchard M, Van Vliet G, De Laet MH, Picard JY. The persistent Müllerian duct syndrome: a molecular approach. J Clin Endocrinol Metab. 1989;681:46-52.
20. Haibel GK, Rojko JL. Persistent Müllerian duct syndrome in a goat. Vet Pathol. 1990;27:135-137.
21. Hoshiya M, Christian BP, Cromie WJ, Kim H, Zhan Y, MacLaughlin DT, Donahoe PK. Persistent Müllerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene. Birth Defects Res A Clin Mol Teratol. 2003;67:868-874.
22. Hutson JM. Comment on: cryptorchidism: incidence, risk factors, and potential role of environment; an update. J Androl. 2003;24:163.
23. Imbeaud S, Belville C, Messika-Zeitoun L, Rey R, di Clemente N, Josso N, Picard JY. A 27 base-pair deletion of the anti-Müllerian type II receptor gene is the most common cause of the persistent Müllerian duct syndrome. Hum Mol Genet. 1996;5:1269-1277.
24. Imbeaud S, Carré-Eusèbe D, Rey R, Belville C, Josso N, Picard JY. Molecular genetics of the persistent Müllerian duct syndrome: a study of 19 families. Hum Mol Genet. 1994;3:125-131.
25. Imbeaud S, Faure E, Lamarre I, Mattei MG, di Clemente N, Tizard R, Carre-Eusebe D, Belville C, Tragethon L, Tonkin C, Nelson J, McAuliffe M, Bidart JM, Lababidi A, Josso N, Cate RL, Picard JY. Insensitivity to anti-Müllerian hormone due to a mutation in the human anti-Müllerian hormone receptor. Nat Genet. 1995;11:382-388.
26. Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR. Requirement of Bmpr1a for Müllerian duct regression during male sexual development. Nat Genet. 2002;32:408-410.
27. Josso N, Belville C, di Clemente N, Picard JY. AMH and AMH receptor defects in persistent Müllerian duct syndrome. Hum Reprod Update. 2005;11:351-356.
28. Josso N, Fekete C, Cachin O, Nezelof C, Rappaport R. Persistence of Müllerian ducts in male pseudohermaphroditism, and its relationship to cryptorchidism. Clin Endocrinol (Oxf). 1983;19:247-258.
29. Jost A. Fetal intersexuality induced by methylandrostenediol in the rat; with reference to a probably similar clinical observation. C R Seances Soc Biol Fil. 1953;147:1930-1933.
30. Jost A. Gonadal hormones in the sex differentiation of the mammalian fetus. In: DeHaan RL, Ursprung H, eds. Organogenesis. New York: Holt, Rinehart & Winston, 1965:621-623.
31. Kazim E. Intra-abdominal seminomas in persistent Müllerian duct syndrome. Urology. 1985;26:290-292.
32. Krstic ZD, Smoljanic Z, Micovic Z, Vukadinovic V, Sretenovic A, Varinac D. Surgical treatment of the Müllerian duct remnants. J Pediatr Surg. 2001;36:870-876.
33. Lee MM, Seah CC, Masiakos PT, Sottas CM, Preffer FI, Donahoe PK, Maclaughlin DT, Hardy MP. Müllerian inhibiting substance type II receptor expression and function in purified rat Leydig cells. Endocrinology. 1999;140:2819-2827.
34. Lima M, Aquino A, Domini M, Ruggeri G, Libri M, Cimador M, Pelusi G. Laparoscopic removal of Müllerian duct remnants in boys. J Urol. 2004;171:364-368.
35. Marshall LS, Oehlert ML, Haskins ME, Selden JR, Patterson DF. Persistent Müllerian duct syndrome in miniature schnauzers. J Am Vet Med Assoc. 1982;181:798-801.
36. Melman A, Leiter E, Perez JM, Driscoll D, Palmer C. The influence of neonatal orchiopexy upon the testis in persistent Müllerian duct syndrome. J Urol. 1981;125:856-858.
37. Messika-Zeitoun L, Gouedard L, Belville C, Dutertre M, Lins L, Imbeaud S, Hughes IA, Picard JY, Josso N, di Clemente N. Autosomal recessive segregation of a truncating mutation of anti-Müllerian type II receptor in a family affected by the persistent Müllerian duet syndrome contrasts with its dominant negative activity in vitro. J Clin Endocrinol Metab. 2001;86:4390-4397.
38. Meyers-Wallen VN, Donahoe PK, Ueno S, Manganaro TF, Patterson DF. Müllerian inhibiting substance is present in testes of dogs with persistent Müllerian duct syndrome. Biol Reprod. 1989;41: 881-888.
39. Meyers-Wallen VN, Lee MM, Manganaro TF, Kuroda T, MacLaughlin D, Donahoe PK. Müllerian inhibiting substance is present in embryonic testes of dogs with persistent Müllerian duct syndrome. Biol Reprod. 1993;48:1410-1418.
40. Meyers-Wallen VN, Manganaro TF, Kuroda T, Concannon PW, MacLaughlin DT, Donahoe PK. The critical period for Müllerian duct regression in the dog embryo. Biol Reprod. 1991;45:626-633.
41. Nickel RF, Ubbink G, van der Gaag I, van Sluijs FJ. Persistent Müllerian duct syndrome in the basset hound. Tijdschr Diergeneeskd. Apr 1992;117(1 suppl):31S.
42. Racine C, Rey R, Forest M, Louis F, Ferre A, Huhtaniemi I, Josso N, di Clemente N. Receptors for anti-Müllerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. Proc Natl Acad Sci U S A. 1998;95:594-599.
43. Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F, Pugniere M, Pourquier D, Gutowski M, Picard JY, Xavier F, Pelegrin A, Navarro-Teulon I. The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J. 2004;379:785-793.
44. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989:E3-E15.
45. Schulman J, Levine SH. Pyometra involving uterus masculinus in a cat. J Am Vet Med Assoc. 1989;194:690-691.
46. Segev DL, Hoshiya Y, Hoshiya M, Tran TT, Carey JL, Stephen AE, MacLaughlin DT, Donahoe PK, Maheswaran S. Müllerian-inhibiting substance regulares NF-kappa B signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci U S A. 2002;99:239-244.
47. Sloan WR, Walsh PC. Familial persistent Müllerian duet syndrome. J Urol. 1976;115:459-461.
48. Snow BW, Rowland RG, Seal GM, Williams SD. Testicular tumor in patient with persistent Müllerian duct syndrome. Urology. 1985;26:495-497.
49. Tank ES, Hatch DA. Müllerian remnant causing bladder outlet obstruction. J Pediatr Surg. 1986;21:77-80.
50. Teixeira J, Donahoe PK. Molecular biology of MIS and its receptors. J Androl. 1996;17:336-341.
51. Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Ingraham HA. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling. Mol Endocrinol. 2001;15:936-945.
52. Wu X, Arumugam R, Baker SP, Lee MM. Pubertal and adult Leydig cell function in Müllerian inhibiting substance-deficient mice. Endocrinology. 2005;146:589-595.
53. Xavier F, Allard S. Anti-Müllerian hormone, beta-catenin and Müllerian duct regression. Mol Cell Endocrinol. 2003;211:115-121.
54. Zenteno JC, Carranza-Lira S, Kofman-Alfaro S. Molecular analysis of the anti-Müllerian hormone, the anti-Müllerian hormone receptor, and galactose-1-phosphate uridy1 transferase genes in patients with the Mayer-Rokitansky-Kuster-Hauser syndrome. Arch Gynecol Obstet. 2004;269:270-273.
55. Zhou B, Watts LM, Hutson JM. Germ cell development in neonatal mouse testes in vitro requires Müllerian inhibiting substance. J Urol. 1993;150:613-616.